II - interní lobbisté a obchodní/podniková/profesní sdružení
podniky a skupiny
Great West Road, 980
TW8 9GS Brentford, Middlesex
(+44) 20 8047 5000
Avenue des Arts 46/b9
(+32) 2 282 40 55
pan Andrew Witty
Chief Executive Officer
paní Sue Middleton
Vice President European Government Affairs
GSK is a science-led global healthcare company.
Our mission is to help people do more, feel better, live longer.
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare that can improve people’s health and well-being, ultimately helping them to live life to its fullest and contribute to the prosperity of their communities.
Our Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Our portfolio is made up of both patent-protected and off patent medicines and we have leading global positions in respiratory disease and HIV.
Our Vaccines business is one of the largest in the world. We have a broad portfolio of over 30 paediatric, adolescent, adult and travel vaccines. In 2014, we distributed approximately 800 million doses in 170 countries.
We develop and market a range of consumer healthcare products based on scientific innovation. We have brands in four main categories: Wellness, Oral Health, Skin Health and Nutrition. These include a number of well-known brands such as Sensodyne, Panadol and Horlicks.
We have a significant global presence with commercial operations in more than 150 countries, a network of 84 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China.
We follow EU initiatives, policies and legislative files related to our Pharmaceuticals, Vaccines and Consumer Healthcare businesses.
This includes topics such as R&D and clinical trials, antimicrobial resistance, data protection, pharmaceutical legislation, medical devices, trade & IP, environment, smoking cessation.
Mainly via the participation of events organized by Trade Associations and Think-Tanks.
EC Expert Group on Rare-Diseases (on behalf of EuropaBio)
100%: 0 75%: 3 50%: 3 25%: 5
The number of persons reflects the full time employment falling under the scope of the register. GSK follows the guidelines provided by EFPIA regarding this registration.
|Jméno||Příjmení||Datum zahájení||Datum ukončení|
|Paulus Lambertus Antonius||VAN HOOF||31/07/2015||29/07/2016|
|Guilherme||MONTEIRO FERREIRA BORGES DOS SANTOS||26/09/2015||25/09/2016|
American Chamber of Commerce to the European Union (AmChamEU)
Association of the European Self-Medication Industry (AESGP)
British Chamber of Commerce in Belgium
European Biopharmaceutical Enterprises (EBE)
European Brands Association (AIM)
European Diagnostic Manufacturers Association (EDMA)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Vaccines Europe (VE)
World Federation of Advertisers (WFA)
01/2014 - 12/2014
>= 1 750 000 € a < 1 999 999 €
10 445 466 €
FP7-People; FP7-NMP; Horizon 2020
In 2013, GSK’s estimated costs attributable to activities covered by the Register were in the range of 600.000-700.000. While GSK maintained activities in scope of the register from 2013 to 2014, the increased figures result from vacancies and the renewed “transparency register implementing guidelines” published 21 January 2015 by the Joint Transparency Register Secretariat.
GSK followed EFPIA’s interpretation and guidance on implementing those guidelines in 2014.
V rámci registrace organizace podepsala kodex chování rejstříku transparentnosti.